Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Abbott Gets FDA Nod To Use Femtosecond Laser Technology For Arcuate Incisions

Healthcare products maker Abbott Laboratories (ABT: Quote) said Friday that the U.S. Food and Drug Administration or FDA has approved usage of the company's iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide. In the U.S., nearly 3 million patients undergo cataract surgery each year.

Factors such as placement, length, depth and radius of curvature are difficult to control through traditional incisions made by hand using surgical knives.

Abbott said that the iFS Laser enables surgeons to make arcuate incisions with greater precision and customization than is possible with a manual technique.

Abbott said that the new use of its iFS Femtosecond laser is available now in the U.S. According to the company, with the new clearance, the iFS Laser will now give surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Jim Mazzo, senior vice president of Abbott Medical Optics, said, "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

The company said study data supported that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

The use of femtosecond lasers for a variety of ophthalmic operations continues to grow, and market forecasts predict that the sector will keep expanding.

In Friday's session, ABT is trading at $59.41, down $0.10 or 0.17 percent on a volume of 2.07 million shares.

Register
To receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.